Free Trial

Mainz Biomed Q4 2023 Earnings Report

Mainz Biomed logo
$4.90 +0.07 (+1.45%)
As of 01/21/2025 04:00 PM Eastern

Mainz Biomed EPS Results

Actual EPS
-$9.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Mainz Biomed Revenue Results

Actual Revenue
$0.22 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mainz Biomed Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Mainz Biomed Earnings Headlines

Mainz Biomed Moves Forward With Pivotal CRC Study After Feasibility Trial
Mainz Biomed initiates U.S. study to evaluate CRC test
Trump’s Inauguration Shocker: “Move Your Cash Now”
Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's issuing this NEW warning about Trump's inauguration.
See More Mainz Biomed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mainz Biomed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mainz Biomed and other key companies, straight to your email.

About Mainz Biomed

Mainz Biomed (NASDAQ:MYNZ) N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

View Mainz Biomed Profile

More Earnings Resources from MarketBeat